<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05006768</url>
  </required_header>
  <id_info>
    <org_study_id>GRC/1/21/940</org_study_id>
    <nct_id>NCT05006768</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Baricitinib From Barcimiant 4 mg Film Coated Tablets (Horus Pharma, Egypt) and Olumiant 4 mg Film Coated Tablets (Eli Lilly Nederland B.V., The Netherlands)</brief_title>
  <official_title>Comparative Randomized, Single Dose, Three Way Three Sequence Two Treatment Partial Replicate Crossover Study to Determine the Bioequivalence of Baricitinib From Barcimiant 4 mg Film Coated Tablets (Horus Pharma, Egypt) and Olumiant 4 mg Film Coated Tablets (Eli Lilly Nederland B.V., The Netherlands)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genuine Research Center, Egypt</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Horus Pharma</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Genuine Research Center, Egypt</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Comparative randomized, single dose, three-way, three-sequence, two treatment, partial&#xD;
      replicate, crossover, open-label study to determine the bioequivalence of Baricitinib from&#xD;
      Barcimiant 4 mg Film Coated Tablets (Horus Pharma, Egypt) and Olumiant 4 mg Film Coated&#xD;
      Tablets (Eli Lilly Nederland B.V., The Netherlands)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Pharmacokinetic Parameters: Cmax, AUC0→t and AUC0→∞ Secondary Pharmacokinetic&#xD;
      Parameters: Ke, tmax and t1/2e. ANOVA using 5% significance level for transformed (with the&#xD;
      90% confidence intervals) and untransformed data of Cmax, AUC0→t and AUC0→∞ and for&#xD;
      untransformed data of Ke, tmax and t1/2e.&#xD;
&#xD;
      The confidence intervals of logarithmically transformed Test/Reference ratios for Cmax,&#xD;
      AUC0→t and AUC0→∞ to be within 80.00-125.00%.&#xD;
&#xD;
      A comprehensive final report will be issued upon the completion of the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 5, 2021</start_date>
  <completion_date type="Actual">June 24, 2021</completion_date>
  <primary_completion_date type="Actual">June 3, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>Up to 48 hours post dose in each treatment period</time_frame>
    <description>Maximal measured plasma concentration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time of the maximum plasma concentration (Tmax)</measure>
    <time_frame>Up to 48 hours post dose in each treatment period</time_frame>
    <description>The amount of time that a drug is present at the maximum concentration in serum</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>T test</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Test drug (Barcimiant) 1 tablet contains 4 mg Baricitinib</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B reference (first dose)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Reference drug (Olumiant) 1 tablet contains 4 mg Baricitinib</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B reference (second dose)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Reference drug (Olumiant) 1 tablet contains 4 mg Baricitinib</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Barcimiant</intervention_name>
    <description>1 tablet contains 4 mg Barcitinib</description>
    <arm_group_label>T test</arm_group_label>
    <other_name>Olumiant</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olumiant (first dose)</intervention_name>
    <description>1 tablet contains 4 mg Barcitinib</description>
    <arm_group_label>B reference (first dose)</arm_group_label>
    <other_name>Olumiant</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olumiant (second dose)</intervention_name>
    <description>1 tablet contains 4 mg Barcitinib</description>
    <arm_group_label>B reference (second dose)</arm_group_label>
    <other_name>Olumiant</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy male or female, age 18 to 55 years, inclusive.&#xD;
&#xD;
          2. Enrolled study participants should have normal liver function tests, blood counts, and&#xD;
             lipid profiles at baseline prior to study drug administration.&#xD;
&#xD;
          3. Clearly healthy males or females, as determined by medical history and physical&#xD;
             examination.&#xD;
&#xD;
          4. Body weight within 15% of normal range according to the accepted normal values for&#xD;
             body mass index (BMI).&#xD;
&#xD;
          5. Medical demographics without evidence of clinically significant deviation from normal&#xD;
             medical condition, eg.: no history of heart, liver, kidney, gastrointestinal, nervous&#xD;
             system, or metabolic abnormalities.&#xD;
&#xD;
          6. Results of clinical laboratory test are within the normal range or with a deviation&#xD;
             that is not considered clinically significant by principal investigator.&#xD;
&#xD;
          7. Females should be on a suitable birth control method.&#xD;
&#xD;
          8. Fully informed subjects that consented to participate in the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects with known allergy to the products tested.&#xD;
&#xD;
          2. Prospective study participants who are tested and confirmed positive for latent&#xD;
             tuberculosis before enrolling in a bioequivalence study.&#xD;
&#xD;
          3. Have a current or recent history (less than [&lt;] 30 days prior to screening and/or &lt;45&#xD;
             days prior to Day -1 in Period 1) of a clinically significant bacterial, fungal&#xD;
             parasitic, viral (not including rhinopharyngitis), or mycobacterial infection&#xD;
&#xD;
          4. Have received live vaccine(s) within 3 months of screening, or intend to during the&#xD;
             study.&#xD;
&#xD;
          5. Female subjects who are pregnant or nursing.&#xD;
&#xD;
          6. Exclude subjects at an increased risk for thrombosis.&#xD;
&#xD;
          7. Acute infection within one week preceding first study drug administration.&#xD;
&#xD;
          8. History of drug or alcohol abuse.&#xD;
&#xD;
          9. Subject does not comply with the stated instruction of not taking any prescription or&#xD;
             non-prescription drugs within two weeks before first study drug administration and&#xD;
             until the end of the study.&#xD;
&#xD;
         10. Subject is on a special diet (for example subject is vegetarian).&#xD;
&#xD;
         11. Subject does not agree not to consume any beverages or foods containing&#xD;
             methyl-xanthenes e.g. caffeine (coffee, tea, cola, chocolate etc.) 48 hours prior to&#xD;
             the study administration of either study period until donating the last sample in each&#xD;
             respective period.&#xD;
&#xD;
         12. Subject does not agree not to consume any beverages or foods containing grapefruit 7&#xD;
             days prior to first study drug administration until the end of the study.&#xD;
&#xD;
         13. Subject has a family history of severe diseases which have direct impact on the study.&#xD;
&#xD;
         14. Participation in a bioequivalence study or in a clinical study within the last 8 weeks&#xD;
             before first study drug administration.&#xD;
&#xD;
         15. Subject intends to be hospitalized within 3 months after first study drug&#xD;
             administration.&#xD;
&#xD;
         16. Subjects who have donated blood or lost more than 500 mL blood within 3 months prior&#xD;
             to the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ahmed Elshafeey, Ph.D. Pharma</last_name>
    <role>Study Director</role>
    <affiliation>Genuine Research Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Genuine Research Center GRC</name>
      <address>
        <city>Cairo</city>
        <zip>11757</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <link>
    <url>http://www.ema.europa.eu/ema</url>
    <description>Note for Guidance on Good Clinical Practice (CPMP/ICH/135/95) The European Agency for the Evaluation of Medicinal Products (EMEA) May 1997</description>
  </link>
  <link>
    <url>http://www.ema.europa.eu/ema</url>
    <description>Note for Guidance on Clinical Safety Data Management; Definitions And Standards for Expedited Reporting (CPMP/ICH/377/95) The European Agency for the Evaluation of Medicinal Products (EMEA) June 1995.</description>
  </link>
  <link>
    <url>https://www.fda.gov/files/drugs/published/Guidance-for-Industry-Bioavailability-and-Bioequivalence-Studies-for-Orally-Administered-Drug-Products---General-Considerations.PDF</url>
    <description>Guidance for Industry: Bioavailability and Bioequivalence studies for orally administered drug products-general considerations. US Dept. of Health and Human Services, food and drug administration (FDA), center for drug evaluation and research (CDER), M</description>
  </link>
  <reference>
    <citation>Chow SC, Wang H. On sample size calculation in bioequivalence trials. J Pharmacokinet Pharmacodyn. 2001 Apr;28(2):155-69. Erratum in: J Pharmacokinet Pharmacodyn. 2002 Feb;29(1):101..</citation>
    <PMID>11381568</PMID>
  </reference>
  <reference>
    <citation>Diletti E, Hauschke D, Steinijans VW. Sample size determination for bioequivalence assessment by means of confidence intervals. Int J Clin Pharmacol Ther Toxicol. 1991 Jan;29(1):1-8.</citation>
    <PMID>2004861</PMID>
  </reference>
  <reference>
    <citation>Schuirmann DJ. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm. 1987 Dec;15(6):657-80.</citation>
    <PMID>3450848</PMID>
  </reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 9, 2021</study_first_submitted>
  <study_first_submitted_qc>August 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 16, 2021</study_first_posted>
  <last_update_submitted>August 9, 2021</last_update_submitted>
  <last_update_submitted_qc>August 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

